Literature DB >> 32224803

Reversible Corneal Endothelial Abnormalities With Netarsudil.

Angelo P Tanna1, Hamed Esfandiari, Kyla Teramoto.   

Abstract

PURPOSE: To report a case of reversible corneal endothelial abnormalities after treatment with netarsudil. OBSERVATION: A 68-year-old woman presented with the complaint of blurred vision soon after starting treatment with the fixed-dose combination of netarsudil and latanoprost (FC-netarsudil-latanoprost). She had been receiving the fixed-dose combination of dorzolamide and timolol and latanoprost for primary open-angle glaucoma until her ophthalmologist switched latanoprost to FC-netarsudil-latanoprost 2 months before referral to our center.Best-corrected visual acuity was 20/20-1 in the right eye and 20/20-3 in the left eye. The slit-lamp biomicroscopic examination was remarkable for a guttata-like abnormality of the corneal endothelium of both eyes. The intraocular pressure was 10 mm Hg in both eyes. Specular microscopy revealed irregularly shaped corneal endothelial cells with indistinct borders between cells. FC-netarsudil-latanoprost was replaced with latanoprost in the left eye but continued in the right eye. Nine weeks later, best-corrected visual acuity remained 20/20-1 in the right eye but it improved to 20/20 in the left eye. Repeat specular microscopy was unchanged in the right eye and was normal in the left eye. CONCLUSION AND IMPORTANCE: Topical therapy with netarsudil can result in guttata-like changes of the corneal endothelium and corneal endothelial cell abnormalities that can be detected with specular microscopy. These abnormalities seem to be transient and resolved upon the cessation of netarsudil. Ophthalmologists should consider the possibility of a corneal endothelial abnormality in patients treated with netarsudil who develop blurred vision.

Entities:  

Year:  2020        PMID: 32224803     DOI: 10.1097/IJG.0000000000001507

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  5 in total

1.  The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes.

Authors:  Eric J Shiuey; Nikki A Mehran; Melih Ustaoglu; Qiang Zhang; Reza Razeghinejad; Aakriti G Shukla; Natasha N Kolomeyer; Jonathan S Myers; Daniel Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-09-22       Impact factor: 3.117

2.  Reticular epithelial edema after penetrating keratoplasty in a patient taking netarsudil.

Authors:  Lauren J Jeang; Ankit S Shah; Jon D Hammer; Sonal S Tuli
Journal:  Digit J Ophthalmol       Date:  2022-06-27

3.  Targeted Delivery of Cell Softening Micelles to Schlemm's Canal Endothelial Cells for Treatment of Glaucoma.

Authors:  Trevor Stack; Michael Vincent; Amir Vahabikashi; Guorong Li; Kristin M Perkumas; W Daniel Stamer; Mark Johnson; Evan Scott
Journal:  Small       Date:  2020-10-04       Impact factor: 13.281

4.  Netarsudil-associated reticular corneal epithelial edema.

Authors:  Jennifer A Tran; Ula V Jurkunas; Jia Yin; Emma C Davies; David A Sola-Del Valle; Teresa C Chen; Michael M Lin
Journal:  Am J Ophthalmol Case Rep       Date:  2022-01-20

5.  "Rapid and reversible alteration in corneal contour and power associated with Netarsudil/Latanoprost".

Authors:  David Chung; Edward J Meier
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.